Ryuji Tabata

Hakodate Central General Hospital

Papers

1

Total Citations

5

H-Index

1

About

Ryuji Tabata is a leading figure in urologic oncology, with a focused expertise in the surgical management of high-risk prostate cancer. His major contributions center on optimizing treatment strategies for patients undergoing robot-assisted radical prostatectomy (RARP), particularly by comparing the efficacy and safety of extended pelvic lymph-node dissection (ePLND) versus neoadjuvant chemohormonal therapy (NCHT). In his most cited work (2023, 5 citations), Tabata retrospectively analyzed 452 patients, providing critical insights into postoperative complications and oncological outcomes, thereby guiding clinical decision-making for this challenging patient population. His research directly addresses the balance between aggressive surgical staging and systemic therapy, helping to refine personalized treatment protocols. While his citation count is still growing, Tabata’s work is already influential in shaping contemporary urologic practice, especially in the context of robotic surgery. His dedication to improving surgical outcomes and his rigorous comparative analyses mark him as an emerging authority in prostate cancer management, offering valuable evidence for clinicians and researchers alike.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy
5 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: Hakodate Central General Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago